关键词： 罗氏 Illumina
2012年12月21日讯 /生物谷BIOON/ --在瑞士报纸L'Agefi报道罗氏有可能再次收购Illumina之后，Illumina股票本周四大涨7%，罗氏股票价格略有小跌。
L'Agefi声称，这一消息可靠但是还未得到证实，这份报纸声称两家公司在上周达成以每股66美元的价格收购意向，这使交易价格将达到81亿美元到82亿美元间。
今年四月份，Illumina拒绝了罗氏的67亿美元的收购要约，罗氏最终于4月20日停止了对Illumina的收购计划。
罗氏发言人对此尚未置评，分析家们对此表示怀疑。（生物谷Bioon.com）
“剧情”回顾
罗氏愿意进行30亿美元规模并购交易
罗氏向Illumina发出敌意收购要约报价57亿美元
Illumina推出毒丸计划回应罗氏
Illumina拒绝罗氏57亿美元收购要约
罗氏做好打持久战的准备
罗氏延长对Illumina收购要约
罗氏施压Illumina称收购失败还有其他选项
Illumina再拒罗氏敌意收购
罗氏再次延长对Illumina敌意收购报价截止期限
罗氏上调收购Illumina报价至65亿美元
Illumina公司拒绝罗氏67亿美元收购要约
Illumina自比苹果 罗氏有意再度上调收购价格
罗氏发表声明—不延长对Illumina公司的收购要约
英文报道：
Shares in Illumina (ILMN.O) jumped 7 percent on Thursday, after Swiss newspaper L'Agefi reported that Roche may have reached an agreement to buy the U.S. gene-sequencing company.
Citing "information that appears trustworthy but could not be verified", the paper said the two parties may have last week agreed on a transaction price of $66 per share which would value the company between $8.1 billion and $8.2 billion.
The paper added that nothing was finalized yet, but that an announcement could come in the first half of January.
Roche spokesman Alexander Klauser said the company did not comment on market rumors.
Roche walked away from a $6.8 billion bid for Illumina in April after shareholders blocked its move to gain seats on the U.S. firm's board. Severin Schwan had earlier ridiculed Illumina's claim to be "the Apple of the genomics business".
Analysts were skeptical about the report.
"The price tag looks quite high as it would represents a premium of 48 percent versus the initial offer a year ago," said Helvea analyst Odile Rundquist. "For a company having revenues of roughly $1 billion, that values the deal at eight times sales."
By 10 a.m. ET shares in Illumina were trading up 7 percent at $55.90. Shares in Roche (ROG.VX) were down 1.3 percent at 184.6 Swiss francs.
